구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab (Imfinzi, Administration of ceralasertib and durvalumab) AstraZeneca·Adv Solid Malig - H&N SCC, ATM Pro… 12 trials |
|---|---|
Overview Program | Administration of ceralasertib and durvalumab |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Adv Solid Malig - H&N SCC, ATM Pro / Def |
Overview Indication | Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | Targeting the DNA damage repair (DDR) pathway |
MoA Biomarker | PD-L1 expression |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | PD |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | thrombocytopenia with Grade 3 anaemia (ceralasertib 320 mg QD for 14 days); and Grade 4 t |
Clinical Safety signal | thrombocytopenia with Grade 3 anaemia (ceralasertib 320 mg QD for 14 days); and Grade 4 t |
Clinical Selected reported efficacy | ORR 9.5% |
Clinical Reported ORR | 9.5% |
Clinical Reported PFS | 2.79 |
Clinical Reported OS | 9.63 |
Clinical Result source | ClinicalTrials.gov NCT03334617 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03334617 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab (Imfinzi, Administration of ceralasertib and durvalumab) AstraZeneca·Adv Solid Malig - H&N SCC, ATM Pro… 12 trials |
|---|---|
Overview Program | Administration of ceralasertib and durvalumab |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Adv Solid Malig - H&N SCC, ATM Pro / Def |
Overview Indication | Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | Targeting the DNA damage repair (DDR) pathway |
MoA Biomarker | PD-L1 expression |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | PD |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | thrombocytopenia with Grade 3 anaemia (ceralasertib 320 mg QD for 14 days); and Grade 4 t |
Clinical Safety signal | thrombocytopenia with Grade 3 anaemia (ceralasertib 320 mg QD for 14 days); and Grade 4 t |
Clinical Selected reported efficacy | ORR 9.5% |
Clinical Reported ORR | 9.5% |
Clinical Reported PFS | 2.79 |
Clinical Reported OS | 9.63 |
Clinical Result source | ClinicalTrials.gov NCT03334617 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03334617 |
추천 비교
추천 비교